RxDoctor Payments Data

Hillary Keeler, NP

Nurse Practitioner · Grand Chute, WINPI 1407529001

Payments from drug & device makers

$2,839in general payments, 2019–2025

Across 115 payments — averaging $24.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$552
  • Edwards Lifesciences$305
  • Johnson & Johnson$273
  • Boston Scientific$263
  • E.r. Squibb & Sons, L.L.C.$188
  • Alnylam Pharmaceuticals Inc.$170
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$2,839100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,839 in reported general payments places this provider in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.

See all nurse practitioner providers in Wisconsin

Medicare billing

Part B allowed, 2024
$25,630
Medicare patients
227
Services billed
444

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban185$194,531
EntrestoSacubitril/Valsartan71$72,391
XareltoRivaroxaban68$63,449
JardianceEmpagliflozin36$43,318
BrilintaTicagrelor46$32,354
Metoprolol Succinate304$6,031
Atorvastatin Calcium228$2,968
Spironolactone193$1,762
Metoprolol Tartrate153$1,727
Furosemide235$1,584
Potassium Chloride72$1,568
ClopidogrelClopidogrel Bisulfate107$1,560
Losartan Potassium119$1,513
Bumetanide38$1,448
Rosuvastatin Calcium104$1,418

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$141$194,531185 claims
NovartisEntresto$552$72,39171 claims
Johnson & JohnsonXarelto$273$63,44968 claims
Boehringer IngelheimJardiance$102$43,31836 claims
AstraZenecaBrilinta$53$32,35446 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.

Other nurse practitioner in Grand Chute

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →